0
     

Report Added
Report already added
Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 5, 3, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 8, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics Inc
Biotest AG
Cellectis SA
Cellective BioTherapy Inc
Chengdu Rongsheng Pharmaceutical Co Ltd
Clinigen Group Plc
CSL Ltd
EmendoBio Inc
Evolve Biologics Inc
Genespire Srl
Graphite Bio Inc
Grifols SA
Grifols Therapeutics Inc
Jasper Therapeutics Inc
Kedrion SpA
Lactiga Inc
Liminal BioSciences Inc
Microgen
Mustang Bio Inc
Noga Therapeutics Ltd
Novartis AG
Octapharma AG
Orchard Therapeutics Plc
Pfizer Inc
Smart Immune SAS
Sumitomo Dainippon Pharma Co Ltd
Taiga Biotechnologies Inc
Takeda Pharmaceutical Co Ltd
X4 Pharmaceuticals Inc
Primary Immune Deficiency (PID) - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
History of Events
BioGam - Drug Profile
Product Description
Mechanism Of Action
Biologic 1 for Genetic Disorders and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
Biologic for Genetic Disorders and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
BT-595 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Severe Combined Immune Deficiency and Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
Cuvitru - Drug Profile
Product Description
Mechanism Of Action
History of Events
EMD-102 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapies for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Artemis for Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
GENE-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GPH-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
IVIG-PEG - Drug Profile
Product Description
Mechanism Of Action
History of Events
JSP-191 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LCTG-001 - Drug Profile
Product Description
Mechanism Of Action
leniolisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
mavorixafor - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-107 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Octanorm - Drug Profile
Product Description
Mechanism Of Action
History of Events
RecIG - Drug Profile
Product Description
Mechanism Of Action
Rethymic - Drug Profile
Product Description
Mechanism Of Action
History of Events
simoladagene autotemcel - Drug Profile
Product Description
Mechanism Of Action
History of Events
sirolimus - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
SMART-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-880 - Drug Profile
Product Description
Mechanism Of Action
TAK-881 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TalX-02 - Drug Profile
Product Description
Mechanism Of Action
TalX-03 - Drug Profile
Product Description
Mechanism Of Action
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
History of Events
X-4P003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Discontinued Products
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor
Oct 04, 2021: X4 Pharmaceuticals completes enrollment in phase 3 mavorixafor trial in patients with WHIM Syndrome
Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results
Jul 13, 2021: First patient treated in KIDCARES10, Kedrion Biopharma pediatric primary immunodeficiency study
May 17, 2021: Evolve Biologics confirms selection of DPR Construction as general contractor for first manufacturing facility in Texas, demonstrating further progress toward commercialization of Its innovative PlasmaCap EBA technology
Apr 01, 2021: First patient enrolled in KIDCARES10, Kedrion Biopharma pediatric Primary immunodeficiency study
Mar 10, 2021: Evolve Biologics provides business update on progress toward commercialization of innovative PlasmaCap EBA technology
Feb 09, 2021: Evolve Biologics completes phase III adult and pediatric trials for PlasmaCap IG (Intravenous Immunoglobulin)
Jan 11, 2021: CARES10 clinical trial: Last patient treated in the USA
Jan 04, 2021: Kedrion Biopharma phase III trial, CARES10, achieves important milestone: last patient treated
Dec 10, 2020: X4 Pharmaceuticals receives rare pediatric disease designation from FDA for Mavorixafor for the treatment of WHIM syndrome
Oct 08, 2020: X4 Pharmaceuticals announces fast track designation granted by the FDA to Mavorixafor for the treatment of WHIM Syndrome
Sep 15, 2020: European Medicines Agency approves label update for HYQVIA (human normal immunoglobulin 10% and recombinant human hyaluronidase), expanding its use to a broader group of patients with secondary immunodeficiencies
Sep 09, 2020: Heyu Medicine's CXCR4 antagonist Mavorixafor obtains clinical trial approval in China
Sep 02, 2020: X4 Pharmaceuticals announces publication of mavorixafor phase 2 clinical data for treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Biotest AG, 2022
Primary Immune Deficiency (PID) - Pipeline by Cellectis SA, 2022
Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2022
Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, 2022
Primary Immune Deficiency (PID) - Pipeline by CSL Ltd, 2022
Primary Immune Deficiency (PID) - Pipeline by EmendoBio Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Genespire Srl, 2022
Primary Immune Deficiency (PID) - Pipeline by Graphite Bio Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Grifols SA, 2022
Primary Immune Deficiency (PID) - Pipeline by Grifols Therapeutics Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Jasper Therapeutics Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Kedrion SpA, 2022
Primary Immune Deficiency (PID) - Pipeline by Lactiga Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Microgen, 2022
Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Noga Therapeutics Ltd, 2022
Primary Immune Deficiency (PID) - Pipeline by Novartis AG, 2022
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, 2022
Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, 2022
Primary Immune Deficiency (PID) - Pipeline by Pfizer Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Smart Immune SAS, 2022
Primary Immune Deficiency (PID) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, 2022
Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, 2022
Primary Immune Deficiency (PID) - Dormant Projects, 2022
Primary Immune Deficiency (PID) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Primary Immune Deficiency (PID), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW